Sphere Medical Holding Regulatory News (SPHR)

30 August 2016

Sphere Medical Holding plc

("Sphere Medical" or the "Company")

Sphere Medical Expands Sales into Belgium

Sphere Medical Holding plc (AIM: SPHR.L), a leading provider of innovative monitoring and diagnostic devices for the critical care setting, announces the first sale of its Proxima system in Belgium with an initial order to the Universitair Ziekenhuis Brussel, a 700 bed teaching hospital conducting scientific research, which has evaluated the Proxima system during the past year.

After the UK and Germany, Belgium is the third country in which Sphere Medical has sold Proxima devices through its direct sales force.

Dr Wolfgang Rencken, Chief Executive Officer of Sphere Medical, said: "Proxima is an innovative product which offers better patient management during a patient's critical period, and faster and more frequent production of blood gas, electrolyte and metabolite results. We are pleased to bring Proxima to patients around Europe and report sales in three countries now. As we look ahead to the launch of Proxima 4, the opportunity to increase potential coverage from around 10% of critical care patients to 40-50% gives us optimism for the future."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

- Ends -

For further information, please contact:

Notes for Editors

About Sphere Medical (AIM: SPHR.L)

Sphere Medical is an innovative point-of-care medical device company. Its Proxima platform measures blood gases, electrolytes and metabolites at the patient's bedside and aims to improve patient care and reduce health system costs. The device is currently sold directly to the critical care market via Sphere Medical's sales force in the UK, Germany, The Netherlands and Belgium. For further information, please visit www.spheremedical.com.